WP 1049
Alternative Names: House-dust-mite-allergy immunotherapy - Worg Pharmaceuticals; WP-1049Latest Information Update: 18 Feb 2022
At a glance
- Originator Biomay
- Developer Worg Pharmaceuticals (Hangzhou)
- Class Allergy immunotherapies; Antiallergics; Peptide vaccines
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hypersensitivity
Highest Development Phases
- Preclinical Hypersensitivity
Most Recent Events
- 18 Feb 2022 WP 1049 is available for licensing in Europe, USA as of 18 Feb 2022. http://www.worgpharma.com/index.php?c=category&id=51
- 18 Feb 2022 Preclinical trials in Hypersensitivity in China (unspecified route) (Worg Pharmaceuticals pipeline, February 2022)
- 31 Dec 2020 Worg Pharmaceuticals acquires WP 1049 from Biomay